BRPI0702847A - formas de dosagem unitária de temozolomida - Google Patents

formas de dosagem unitária de temozolomida

Info

Publication number
BRPI0702847A
BRPI0702847A BRPI0702847-4A BRPI0702847A BRPI0702847A BR PI0702847 A BRPI0702847 A BR PI0702847A BR PI0702847 A BRPI0702847 A BR PI0702847A BR PI0702847 A BRPI0702847 A BR PI0702847A
Authority
BR
Brazil
Prior art keywords
dosage forms
unit dosage
temozolomide
relates
methods
Prior art date
Application number
BRPI0702847-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Jacqueline Rose Bersch
Mark Manzo
Sumant Ramachandra
Original Assignee
Schering Corportation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corportation filed Critical Schering Corportation
Publication of BRPI0702847A publication Critical patent/BRPI0702847A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0702847-4A 2006-06-26 2007-06-25 formas de dosagem unitária de temozolomida BRPI0702847A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26
PCT/US2007/014761 WO2008002544A2 (fr) 2006-06-26 2007-06-25 Doses uniques de témozolomide

Publications (1)

Publication Number Publication Date
BRPI0702847A true BRPI0702847A (pt) 2008-04-01

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0702847-4A BRPI0702847A (pt) 2006-06-26 2007-06-25 formas de dosagem unitária de temozolomida

Country Status (13)

Country Link
EP (1) EP1901740A2 (fr)
JP (1) JP2008534692A (fr)
KR (2) KR20100055543A (fr)
CN (1) CN101309686A (fr)
AR (1) AR061618A1 (fr)
AU (1) AU2007221979A1 (fr)
BR (1) BRPI0702847A (fr)
CA (1) CA2610439A1 (fr)
CL (1) CL2007001864A1 (fr)
NO (1) NO20074913L (fr)
TW (1) TWI326598B (fr)
WO (1) WO2008002544A2 (fr)
ZA (1) ZA200708280B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
US10744171B2 (en) * 2016-03-21 2020-08-18 Duke University Sequential anti-cancer treatment
US11147810B2 (en) 2017-03-13 2021-10-19 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251987T3 (es) * 1999-03-30 2006-05-16 Schering Corporation Tratamiento mejorado del cancer con temozolomida.
US20060100188A1 (en) * 2004-11-09 2006-05-11 Chen Zong Treatment methods

Also Published As

Publication number Publication date
WO2008002544A2 (fr) 2008-01-03
WO2008002544A3 (fr) 2008-02-07
KR20080015777A (ko) 2008-02-20
JP2008534692A (ja) 2008-08-28
AR061618A1 (es) 2008-09-10
CN101309686A (zh) 2008-11-19
ZA200708280B (en) 2009-03-25
EP1901740A2 (fr) 2008-03-26
AU2007221979A9 (en) 2008-01-10
KR20100055543A (ko) 2010-05-26
AU2007221979A1 (en) 2008-01-10
NO20074913L (no) 2009-03-26
TWI326598B (en) 2010-07-01
CA2610439A1 (fr) 2007-12-26
TW200808803A (en) 2008-02-16
CL2007001864A1 (es) 2008-02-08

Similar Documents

Publication Publication Date Title
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
CO6361917A2 (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
MY161656A (en) Therapeutic use of diaminophenothiazines
MY160041A (en) Compositions and methods for treating parasitic infections
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
PH12013501790B1 (en) Use of dpp iv inhibitors
ECSP11010824A (es) Tratamiento para diabetes en pacientes inapropiados para terapia con metformina.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
BRPI0919876A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
BRPI0914678A8 (pt) Dispositivo dispensador para vaso sanitário e processo para distribuir uma composição de tratamento a um dispositivo sanitário
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
BRPI0710405B8 (pt) comprimido de racecadotril, processo de preparação de um comprimido de racecadotril e uso de racecadotril
MY150931A (en) Substituted oxazolidinones and their use
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BRPI0702847A (pt) formas de dosagem unitária de temozolomida
NZ598124A (en) Compounds for treatment of inflammation
DK2155179T3 (da) Axomadol til smertebehandling arthrose
UA106357C2 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2228 DE 17/09/2013.